Immunoadsorption: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Notjusttired (talk | contribs) m (→See also: link) |
Notjusttired (talk | contribs) (article outline, ref improvements, theory) |
||
Line 1: | Line 1: | ||
'''Immunoadsorption''' is the technique by which pathogenic substances, especially undesirable antibodies, are removed from blood plasma. | '''Immunoadsorption''' is the technique by which pathogenic substances, especially undesirable antibodies, are removed from blood [[plasma]]. Immunoadsorption is considered to have fewer adverse effects than the use of therapeutic plasma exchange.<ref name="Pham, 2013">{{Citation | ||
| last1 = Pham | first1 = Huy P. | authorlink1 = | |||
| last2 = Schwartz | first2 = Joseph | authorlink2 = | |||
| title = Chapter 79 – Immunoadsorption | |||
| journal = Transfusion Medicine and Hemostasis | volume = | issue = | page = 525–527| date = 2013 | |||
| pmid = | doi = 10.1016/B978-0-12-397164-7.00079-3}} | |||
</ref> Several medical conditions, such as [[multiple sclerosis]]<ref name="Koziolek2018">Journal of Neuroinflammation (2012) 9:80. https://doi.org/10.1186/1742-2094-9-80</ref> and chronic inflammatory demyelinating polyneuropathy (CIDP)<ref name="Lehmann2013">Chapter 23 - Treatment of chronic inflammatory demyelinating polyradiculoneuropathy, Handbook of Clinical Neurology | |||
Volume 115, 2013, Pages 415-427, https://doi.org/10.1016/B978-0-444-52902-2.00023-0</ref> may use immunoadsorption as part of their medical regimen. | Volume 115, 2013, Pages 415-427, https://doi.org/10.1016/B978-0-444-52902-2.00023-0</ref> may use immunoadsorption as part of their medical regimen. | ||
== | ==Theory== | ||
*2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME<ref>Scheibenbogen C, Loebel M, Freitag H, Krueger A, Bauer S, Antelmann M, et al. (2018) Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE 13(3): e0193672. https://doi.org/10.1371/journal.pone.0193672</ref> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672 (Full Text)] | A number of studies have found that a subset of [[ME/CFS]] patients have abnormal autoantibodies in their blood; immunoadsorption could be used to remove these autoantibodies with the aim of improving symptoms or potentially curing [[ME/CFS]] in those patients.<ref name="Scheibenbogen2018" /> | ||
==Evidence== | |||
*2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME<ref name="Scheibenbogen2018">Scheibenbogen C, Loebel M, Freitag H, Krueger A, Bauer S, Antelmann M, et al. (2018) Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE 13(3): e0193672. https://doi.org/10.1371/journal.pone.0193672</ref> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672 (Full Text)] | |||
==Clinicians== | |||
==Risks and safety== | |||
==Costs and availability== | |||
==Learn more== | ==Learn more== | ||
Line 11: | Line 26: | ||
==See also== | ==See also== | ||
*[[Autoimmune hypothesis]] | *[[Autoimmune hypothesis]] | ||
*[[Autoantibody]] | |||
*[[Carmen Scheibenbogen]] | *[[Carmen Scheibenbogen]] | ||
==References== | ==References== | ||
{{Reflist}} | |||
{{ | |||
}} | |||
[[Category:Potential treatments]] | [[Category:Potential treatments]] |
Revision as of 15:28, September 28, 2021
Immunoadsorption is the technique by which pathogenic substances, especially undesirable antibodies, are removed from blood plasma. Immunoadsorption is considered to have fewer adverse effects than the use of therapeutic plasma exchange.[1] Several medical conditions, such as multiple sclerosis[2] and chronic inflammatory demyelinating polyneuropathy (CIDP)[3] may use immunoadsorption as part of their medical regimen.
Theory[edit | edit source]
A number of studies have found that a subset of ME/CFS patients have abnormal autoantibodies in their blood; immunoadsorption could be used to remove these autoantibodies with the aim of improving symptoms or potentially curing ME/CFS in those patients.[4]
Evidence[edit | edit source]
- 2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME[4] (Full Text)
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Learn more[edit | edit source]
- Wikipedia page for Immunoadsorption
- 2018, Hope for an ME/CFS Autoimmune Subset: A German Researcher Steps Forward (Carmen Scheibenbogen)
See also[edit | edit source]
References[edit | edit source]
- ↑ Pham, Huy P.; Schwartz, Joseph (2013), "Chapter 79 – Immunoadsorption", Transfusion Medicine and Hemostasis: 525–527, doi:10.1016/B978-0-12-397164-7.00079-3
- ↑ Journal of Neuroinflammation (2012) 9:80. https://doi.org/10.1186/1742-2094-9-80
- ↑ Chapter 23 - Treatment of chronic inflammatory demyelinating polyradiculoneuropathy, Handbook of Clinical Neurology Volume 115, 2013, Pages 415-427, https://doi.org/10.1016/B978-0-444-52902-2.00023-0
- ↑ 4.0 4.1 Scheibenbogen C, Loebel M, Freitag H, Krueger A, Bauer S, Antelmann M, et al. (2018) Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE 13(3): e0193672. https://doi.org/10.1371/journal.pone.0193672